Viking Therapeutics ( ($VKTX) ) has risen by 7.76%. Read on to learn why. Viking Therapeutics has seen a notable 7.76% ...

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $60.0 for Viking Therapeutics, spanning the last three ...

Every investor in Viking Therapeutics, Inc. (NASDAQ:VKTX) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 70% ownership.

Viking Therapeutics reported a solid financial standing with $808 million in cash, cash equivalents, and short-term investments. This strong cash position provides a substantial financial runway to ...

Viking Therapeutics is targeting two monster markets. David Jagielski (CRISPR Therapeutics): Biotech company CRISPR ...

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Viking Therapeutics, with a price target of $70.00. The company’s shares closed yesterday at $33.50. Take ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...

Viking Therapeutics: Soaring Stock, But Is it Worth the Ride? Viking Therapeutics has been a hot stock in 2024, with its share price skyrocketing over 240% since the start of the year.

Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...